Health Catalyst, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Health Catalyst, Inc. on February 26, 2025. The filing primarily serves to announce the Company's financial results for the quarter and fiscal year ended December 31, 2024, and to disclose a change in Board composition. Detailed financial metrics and guidance are contained in attached Exhibits 99.1 and 99.2, which are incorporated by reference but not reproduced in the text of this filing.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being available in the attached press release (Exhibit 99.1) and the summary of 2024 Financial Highlights (Exhibit 99.2). The Company's forward-looking statements reference expectations regarding Platform Client bookings, Dollar-based Retention Rate (Tech + TEMS), revenue growth, Adjusted EBITDA, Adjusted EBITDA margin, and the 'Rule of 30' profile for the technology business unit.
Material Changes and Corporate Governance
- Board Resignation: Anita Pramoda resigned from the Board of Directors, effective March 1, 2025. She also stepped down from the compensation and transactions committees.
- Reason for Departure: The resignation is not the result of any disagreement or conflict with the Company.
- Compensation Adjustment: In recognition of her service, the Board approved the acceleration of vesting for 20,807 Restricted Stock Units (RSUs) held by Ms. Pramoda, which were originally scheduled to vest in June 2025.
Guidance, Outlook, and Risks
The filing includes forward-looking statements regarding the Company's 2025 guidance and key themes. Management expects to provide updates on operating performance, including revenue growth and Adjusted EBITDA metrics. The Company explicitly states that actual results may differ materially from expectations due to risks and uncertainties, including changes in financial performance and unplanned events. The Company does not intend to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Review Exhibit 99.1 for specific Q4 and full-year 2024 revenue, Adjusted EBITDA, and cash flow figures.
- Examine Exhibit 99.2 for detailed 2025 financial guidance and the 'Rule of 30' targets for the technology business unit.
- Verify the impact of the accelerated RSU vesting on the Company's stock-based compensation expense for the upcoming quarter.
- Confirm the timeline for the appointment of a new Board member to replace Anita Pramoda.